Friday, 06 Dec 2019

You are here

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

  1. 30 pts with GCA were assessed by MRA - Less than half had normal MRA at baseline and MRA were weakly sensitive to Clinical change. This preliminary report suggests MRA is NOT useful or predictive in MRA https://t.co/aheWOMKtCE
  2. NICE reverses its Dec 2017 rejection and now approves Tocilizumab for use in Giant Cell Arteritis - specifically those with repeated relapses, or those who don't respond to steroids. https://t.co/tOmacr9ymX
  3. Comparing patients who travel by air vs those by land to/from hospital after TKR, THR, finds 3 fold higher rates of VTE (1.64% vs 0.58%) https://t.co/lFPk510fSv
  4. Study of 176 RA patients shows that those who eat fish 2 or more times per week have better disease control with significantly lower DAS28 scores. For each additional serving of fish per week, DAS28-CRP was significantly reduced by 0.18. https://t.co/vbsyv0SxSU
  5. Compared to diet/lifestyle modification in obese diabetic pts - bariatric surgery surgery patients are more likely to go off DM meds; 17 X more likely with gastric bypass, 7X more likely w/ Sleeve gastrectomy & 4X more likely w/ gastric lap band surgery. https://t.co/vYY2K0ow7J
  6. HUMOR trial - 51 pts shows that Humira is NOT effective in erosive OA - does not reduce pain, synovitis or BMLs after 12 weeks. https://t.co/bet8amKDZ9
  7. Rituximab associated adverse events are more common in treating lymphoma/leukemia ( 25-36%) than with autoimmune disease (9-17%) and are more common with splenomegaly, anemia, hx of allergies, age. https://t.co/gUREPFvbUb
  8. Tofacitinib - No dose adjustment is needed with mild renal impairment. Drug has not been studied in RA/PsA pts with baseline creatinine clearance < 40 mL/ min https://t.co/AvgEzObEAa
  9. FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis  
  10. Opioid Overdoses Jump 30% in 2017 
  11. Opioids No Better than NSAIDs at Chronic Pain  
  12. Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast - Monitoring Methotrexate Safety (12-6-19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

#WomenInRheumatology: Is There a Speaker Gender Gap at ACR Meetings?

Recent studies have quantified the gender gap among speakers at academic conferences. The largest study of 181 medical conferences held in North America over one decade found an increase in the proportion of female speakers from 25 to 34% over time, and that the underrepresentation of women was more marked at surgical compared to medical conferences.

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

Hepatitis C-Related Cryoglobulinemic Vasculitis

Flares of vasculitis can still be a problem after hepatitis C-related cryoglobulinemic vasculitis patients are cured of their hepatitis C by direct-acting antivirals, as demonstrated by data from four registries presented at ACR 2019 in Atlanta, Georgia.

ACR 2019 - Report from Day One (Sunday)

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis